Ed Barnes
General Manager
Ed is the General Manager for the US Orphan Disease Rx business unit at Biocodex, Inc. Ed has 30 years of pharmaceutical experience including 20 years in Orphan Disease.
As the General Manager, Ed is responsible for overseeing daily operations of the business unit and ensuring the creation and implementation of strategies designed to grow the business while supporting the healthcare providers and patient communities.
Prior to Biocodex, Ed has led and been a part of teams designed to build, launch, and grow specialty medications in the oncology market.
Ed holds a bachelor’s degree in Marketing from The University of Maryland, College Park
Scott Koppang
Chief Compliance Officer
Scott is Head of Pharmaceutical Affairs and Chief Compliance Officer for the Rx US business unit at Biocodex, Inc. He joined Biocodex in 2019 and has brought 28 years of pharmaceutical and biotech industry experience across more than 22 disease states and 16 product launches.
Scott is responsible for oversight of Compliance, Regulatory, and Pharmacovigilance.
Prior to Biocodex, Scott spent the first 14 years of his career at Boehringer Ingelheim Pharmaceuticals in both sales and managed markets leadership roles. He has since had roles of increasing responsibility at Salix Pharmaceuticals, MiddleBrook Pharmaceuticals, Avanir Pharmaceutical, and Scilex Pharmaceuticals. During his career he also held positions in compliance with oversight of clinical, medical affairs, and commercial.
Scott holds a Bachelor of Science in Marketing from San Diego State University, Certification in Healthcare Compliance from Seton Hall University School of Law, and is a Certified Compliance and Ethics Professional (CCEP).
Dr. Carla Schad
Medical Officer
Carla is the Medical Officer for the US Orphan Disease Rx business unit at Biocodex, Inc. Carla has 17+ years of pharmaceutical experience, including 7 years in Orphan Disease.
As the US Medical Officer, Carla is responsible for overseeing the operations of US Medical Affairs.
Prior to Biocodex, Carla has focused her pharma career primarily within the Epilepsy therapeutic area; launching multiple anti-seizure medications and most recently leading Field Medical Teams and overseeing Medical Strategy for Dravet Syndrome and Lennox Gastaut Syndrome indications at Zogenix, Inc (now UCB).
Carla has a patient-centric philosophy and works very closely with stakeholders to improve the lives of patients and their families.
Carla is a child neurologist by training; attending Medical School at the University of Missouri; and completing Pediatric Residency and Child Neurology Fellowship at Arkansas Children’s Hospital in Little Rock. She also holds a Master’s in Biology, with emphasis in neuroscience.
